Drug Approval | August 12, 2021
Cipla receives USFDA approval for Difluprednate Ophthalmic Emulsion 0.05%
It’s an AB-rated generic therapeutic version of Durezol
It’s an AB-rated generic therapeutic version of Durezol
A treatment to prevent extreme symptoms and cut hospitalisation
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The collaboration will support Canada with direct access to rapid pandemic response capabilities
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
The goal for the project is the identification and optimization of anti-viral compounds.
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
The transaction is expected to close in the Q4FY22
Subscribe To Our Newsletter & Stay Updated
